6.3
アドレナリン受容体：αサブタイプ
アドレノ受容体は、カテコールアミン作動薬の強さに基づいてαとꞵのクラスに分類されます。αアドレノ受容体のカテコールアミンの強さの順序は以下の通りです：
アドレナリン ≥ ノルアドレナリン >> イソプレナリン
αアドレノ受容体はさらにα1型とα2型に分けられます。
α1アドレノ受容体：これらの受容体…
ɑ-アドレナリン受容体は、ISOよりもAdrおよびNAに対して高い親和性を示します。
それらは、さまざまな要因に基づいて ɑ1 と ɑ2 のサブタイプに分類されます。
刺激を受けると、ɑ1受容体はホスホリパーゼCを活性化し、IP3とDAGを二次メッセンジャーとして放出します。
それらはシナプス後エフェクター器官、特に心血管系と消化管系の平滑筋に存在し、血管収縮、血圧上昇、消化管筋の弛緩に関与しています。
ɑ2受容体刺激は、アデニリルシクラーゼを阻害し、cAMP産生を減少させ、イオンチャネルを調節します。
それらは主に自律神経終末、膵臓ベータ細胞、血管平滑筋、および血小板に存在します。それらは、自律神経伝達物質とインスリンの放出、血管平滑筋の収縮および血小板凝集に影響を与える。
ɑ1およびɑ2受容体は、サブタイプ選択的薬物に基づいて3つのサブタイプに細分されます。例えば、前立腺肥大症の治療に使用されるタムスロシンは、前立腺のɑ1-A受容体を血管のɑ1-B受容体よりも優先的に阻害するため、心血管系の副作用が少なくなります。
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between α1 and α2 adrenergic receptors?
α1 receptors are located postsynaptically on effector organs and activate phospholipase C, releasing IP3 and DAG as secondary messengers, causing vasoconstriction and increased blood pressure. α2 receptors are predominantly presynaptic on nerve terminals and pancreatic beta cells, inhibiting adenylyl cyclase to decrease cAMP production, modulating neurotransmitter release and insulin secretion.
Q2: How do α1 receptors affect smooth muscle in the cardiovascular and GI systems?
α1 receptor stimulation activates the phospholipase C pathway, releasing IP3 and DAG as secondary messengers. In cardiovascular smooth muscle, this causes vasoconstriction and increased blood pressure. In GI smooth muscle, α1 activation leads to muscle relaxation, reducing GI motility and contractions.
Q3: What are the main locations and functions of α2 adrenergic receptors?
α2 receptors are predominantly located on autonomic nerve terminals, pancreatic beta cells, vascular smooth muscles, and platelets. Upon stimulation, they inhibit adenylyl cyclase and decrease cAMP production, modulating the release of autonomic neurotransmitters and insulin, controlling vascular smooth muscle contraction, and affecting platelet aggregation.
Q4: Why does tamsulosin have fewer cardiovascular side effects than other α-blockers?
Tamsulosin preferentially inhibits α1-A receptors in the prostate gland over α1-B receptors in blood vessels. This receptor subtype selectivity allows the drug to treat prostatic hyperplasia effectively while minimizing cardiovascular effects like hypotension that occur when α1-B receptors in blood vessels are blocked.
Q5: How do α1 and α2 receptors differ in their catecholamine potency?
Both α1 and α2 receptors show higher affinity for adrenaline and noradrenaline than isoprenaline. However, α1 receptors are classified based on their postsynaptic location and phospholipase C activation, while α2 receptors are classified by their presynaptic location and adenylyl cyclase inhibition, reflecting distinct functional roles in the autonomic nervous system.
Q6: What are the three subtypes of α1 and α2 receptors?
α1 receptors are subdivided into α1-A, α1-B, and α1-D subtypes, while α2 receptors are subdivided into α2-A, α2-B, and α2-C subtypes. These subdivisions are based on subtype-selective drugs and their differential tissue distribution, allowing for more precise pharmacological targeting and understanding of drug-receptor selectivity.
Q7: How does α2 receptor stimulation affect ion channels and cAMP levels?
α2 receptor activation inhibits adenylyl cyclase, decreasing intracellular cAMP production and causing closure of ion channels. This mechanism contrasts with α1 receptors, which activate phospholipase C. The reduced cAMP and ion channel closure modulate autonomic neurotransmitter release and regulate vascular smooth muscle and platelet function.